Finn, Warnke & Gayton, LLP Announces Final Notice of Asset Sale of Successful Phase I & II Clinical Data for Parkinson's Disease from Vector Neuroscience

Share Article

Final Notice before Public Auction in Newark, NJ; Clinical data from successful Phase 1 and Phase 2 trials of a potential gene therapy treatment for Parkinson’s Disease are for sale.

Joseph F. Finn, Jr. C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP ("FWG"), announces the final notice of the sale of certain assets from Vector Neurosciences LLC of Livingston, NJ (“Vector”) that were formerly owned by Neurologix, Inc., including clinical data from successful Phase 1 and Phase 2 trials of a potential gene therapy treatment for Parkinson’s Disease.

In June 2010, Neurologix announced successful results of its Phase 2 trials of NLX-P101, its investigational gene therapy for advanced Parkinson's disease. Patients in the Phase 2 trial who were administered NLX-P101 achieved “statistically significant and clinically meaningful improvements” in their motor function scores without their standard medication, in comparison with control subject patients who were treated with “sham surgery." The clinical data, and certain of the intellectual property owned or used in the Phase 2 trials, are part of the former assets of Neurologix being offered for sale. Certain other intellectual property is no longer licensed by Neurologix, and is therefore excluded from the assets offered for sale.

The Neurologix assets offered for sale include the patents and intellectual property described below, as well as accounts, general intangibles, clinical trial data and records, and equipment. Also included are additional files, records, office equipment and certain tangible personal property formerly used by Neurologix (certain physical assets located in West Berlin, NJ).

The intellectual property of Neurologix included in the offer for sale consists of certain patents, patent applications, and rights under certain patent licensing agreements. By serial number, the patents include No. 6,436,708 (Delivery System for Gene Therapy to the Brain), No. 7,527,785 (Novel Glutamic Acid Decarboxylase Chimera and Methods of Use), and No. 7,723,288 (Methods and compositions for the treatment of neurological disease).

By serial number, the patent applications include Nos. 2004281764(AU) & 04795081.1(EP) (Methods and compositions for the treatment of neurological disease), No. 12/714,613 (Methods and compositions for the treatment of neurological disease), No. 10/769,182 (Methods and Compositions for use in Interventional Pharmacogenomics), No. 11/255,637 (Use of Apoptosis Inhibiting Compound in Neurological Disorders), Nos. 06 77 1671.2 (EU) & 2610164 (CA) (Novel Glutamic Acid Decarboxylase Chimera and Methods of Use), No. 12/409,837 (Novel Glutamic Acid Decarboxylase Chimera and Methods of Use), No. 11/888,556 (Novel Consensus GAD and Methods of Use), No. 12/261,451 (A Novel Gene Therapy Approach for Treating The Metabolic Disorder Obesity), No. 12/433,098 (A Novel Gene Therapy Approach for Treating The Metabolic Disorder Obesity), No. 61/301,396 (Production of Recombinant Virus).

Also being sold are rights to use certain third party patents (as qualified, limited, or restricted by certain licensing agreements) including Nos. 6,156,535 & 6,159,948 (Mammalian IAP gene family, primers, probes and detection methods).

Vector possesses a security interest. Vector recently acquired rights to the patents, intellectual property and other assets from the senior lenders and noteholders of Neurologix, which Vector will offer for sale at a public auction to be held on Thursday April 14, 2016 at 10:00 a.m. at the offices of McCarter & English, LLP, 100 Mulberry Street, Four Gateway Center, Newark, New Jersey. Vector reserves the right to credit bit on the patents, intellectual property and other assets up to the amount of $9,923,559.22.

Persons interested in bidding must sign a Non-Disclosure Agreement ("NDA") before receiving a bid package. The NDA may be obtained by contacting FWG – IPSaleServices(at)finnwarnkegayton(dot)com or (781) 237 – 8840.

Bid packages including more specific information on the patents (including any corresponding foreign issued patents), intellectual property and other assets being offered for sale will be provided by email upon receipt of an executed NDA.

About Finn, Warnke & Gayton, LLP:

Joseph F. Finn, Jr. C.P.A., is the founding partner of Finn, Warnke & Gayton, LLP
(http://www.finnwarnkegayton.com) Certified Public Accountants of Wellesley Hills, Massachusetts.

FWG has liquidated a number of patent portfolios specific to CNS, and gene therapies.

For further information, please contact Joseph F. Finn, Jr. C.P.A. at (781) 237 – 8840 or jffinnjr(at)finnwarnkegayton(dot)com.
SOURCE Joseph F. Finn, Jr. C.P.A.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Finn
Visit website